Bayer To Expand Aspirin Production

10 September 1995

German chemical and pharmaceutical company Bayer is to increase sales of aspirin to over 1 billion Deutschemarks ($683.5 million) by the year 2000.

Werner Spinner, head of the consumer care sector, said that aspirin would generate sales of 750 million marks - 200 million marks in Germany alone.

Bayer's aspirin sales have risen 15% in each of the last five years and expansion at the firm's self-medication plant at Bitterfeld will boost annual output of self-medication products to 3.5 billion tablets - with increased volume of aspirin together with Alka-Seltzer tablets and the antacid Talcid.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight